Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience
Blood Adv
.
2023 Apr 25;7(8):1351-1355.
doi: 10.1182/bloodadvances.2022007937.
Authors
Bahga Katamesh
1
,
Ahmad Nanaa
1
2
,
Rong He
3
,
David Viswanatha
3
,
Phuong Nguyen
3
,
Patricia Greipp
3
,
Kurt Bessonen
4
,
Naseema Gangat
1
,
Kebede Begna
1
,
Abhishek Mangaonkar
1
,
Mrinal Patnaik
1
,
William J Hogan
1
,
Ayalew Tefferi
1
,
Mark Litzow
1
,
Mithun Vinod Shah
1
,
Cecilia Arana Yi
5
,
James Foran
6
,
Talha Badar
6
,
Hassan B Alkhateeb
1
,
Aref Al-Kali
1
Affiliations
1
Division of Hematology, Mayo Clinic, Rochester, MN.
2
John H. Stroger, Jr. Hospital of Cook County, Chicago, IL.
3
Division of Hematopathology, Mayo Clinic, Rochester, MN.
4
Division of Molecular Hematology, Mayo Clinic, Rochester, MN.
5
Division of Hematology, Mayo Clinic, Scottsdale, AZ.
6
Division of Hematology, Mayo Clinic, Jacksonville, FL.
PMID:
36477202
PMCID:
PMC10139934
DOI:
10.1182/bloodadvances.2022007937
No abstract available
MeSH terms
Cell Cycle Proteins / genetics
Humans
Mutation
Myeloproliferative Disorders* / diagnosis
Myeloproliferative Disorders* / genetics
Neoplasms* / genetics
Prognosis
Substances
STAG2 protein, human
Cell Cycle Proteins